Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Beneish M-Score : 0.00 (As of Jun. 05, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Parnell Pharmaceuticals Holdings's Beneish M-Score or its related term are showing as below:

During the past 7 years, the highest Beneish M-Score of Parnell Pharmaceuticals Holdings was 0.00. The lowest was 0.00. And the median was 0.00.

Parnell Pharmaceuticals Holdings Beneish M-Score Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Beneish M-Score Chart

Parnell Pharmaceuticals Holdings Annual Data

Trend

Jun12

Jun13

Jun14

Dec15

Dec16

Dec17

Dec18

Beneish M-Score

Get a 7-Day Free Trial

-2.48

-2.49

-4.02

-5.78

-2.19

Parnell Pharmaceuticals Holdings Semi-Annual Data
	Jun12	Jun13	Jun14	Dec15	Dec16	Dec17	Dec18
Beneish M-Score	Get a 7-Day Free Trial			-2.48	-2.49	-4.02	-5.78	-2.19

Competitive Comparison of Parnell Pharmaceuticals Holdings's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parnell Pharmaceuticals Holdings's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's Beneish M-Score falls into.

Parnell Pharmaceuticals Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Parnell Pharmaceuticals Holdings for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 0.4906

0.528 * 0.8387

0.404 * 0.9668

0.892 * 1.3014

0.115 * 2.1415

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 0.4311

4.679 * -0.06445

0.327 * 1.142

-2.90

This Year (Dec18) TTM:

Last Year (Dec17) TTM:

Total Receivables was $1.25 Mil.
Revenue was $19.03 Mil.
Gross Profit was $11.13 Mil.
Total Current Assets was $7.01 Mil.
Total Assets was $24.00 Mil.
Property, Plant and Equipment(Net PPE) was $7.59 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.90 Mil.
Selling, General, & Admin. Expense(SGA) was $8.36 Mil.
Total Current Liabilities was $4.85 Mil.
Long-Term Debt & Capital Lease Obligation was $32.28 Mil.
Net Income was $0.09 Mil.
Gross Profit was $2.80 Mil.
Cash Flow from Operations was $-1.16 Mil.

Total Receivables was $1.95 Mil.
Revenue was $14.62 Mil.
Gross Profit was $7.17 Mil.
Total Current Assets was $5.64 Mil.
Total Assets was $23.09 Mil.
Property, Plant and Equipment(Net PPE) was $8.10 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.08 Mil.
Selling, General, & Admin. Expense(SGA) was $14.91 Mil.
Total Current Liabilities was $6.68 Mil.
Long-Term Debt & Capital Lease Obligation was $24.60 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(1.247 / 19.031)	/	(1.953 / 14.623)
	=	0.065525	/	0.133557
	=	0.4906

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(7.171 / 14.623)	/	(11.128 / 19.031)
	=	0.490392	/	0.58473
	=	0.8387

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (7.01 + 7.594) / 24.003)	/	(1 - (5.64 + 8.099) / 23.092)
	=	0.391576	/	0.405032
	=	0.9668

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	19.031	/	14.623
	=	1.3014

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(6.083 / (6.083 + 8.099))	/	(1.902 / (1.902 + 7.594))
	=	0.428924	/	0.200295
	=	2.1415

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(8.364 / 19.031)	/	(14.908 / 14.623)
	=	0.439493	/	1.01949
	=	0.4311

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((32.282 + 4.849) / 24.003)	/	((24.599 + 6.68) / 23.092)
	=	1.546932	/	1.354538
	=	1.142

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(0.093 - 2.801	-	-1.161)	/	24.003
	=	-0.06445

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Parnell Pharmaceuticals Holdings has a M-score of -2.90 suggests that the company is unlikely to be a manipulator.

Parnell Pharmaceuticals Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015

Website

https://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.